Tag:

Humira

Latest Headlines

Latest Headlines

Can Amgen's marketing muscle vault its Humira biosim ahead of rivals?

The market for Humira is a large one: the med raked in $11.02 billion last year to top the list of the world's best-selling drugs. So it's no surprise that biosimilar developers are going after a piece of that market--including Amgen, which released some head-to-head data last week that could help it make its regulatory case.

Judge tosses RICO claims over AbbVie's Humira, AndroGel copay cards

AbbVie may be under fire from the Federal Trade Commission for delaying AndroGel generics, but it won't have to face racketeering claims over its generics-fighting sales tactics.

With Shire deal in the bag, Humira leap helps AbbVie hold its own

AbbVie may have just struck a deal with Shire in order to diversify beyond its top drug, Humira. But that doesn't mean the drug isn't steamrolling.

Which big brands will still be bringing in the big bucks in 2020?

Best-selling drugs did well for themselves in 2013, churning out more than $76 billion in sales. But big-name brands could stand the test of time and help the top 10 rake in more than $80 billion in 2020, according to a new report.

Which big brands will still be bringing in the big bucks in 2020?

Best-selling drugs did well for themselves in 2013, churning out more than $76 billion in sales. But big-name brands could stand the test of time and help the top 10 rake in more than $80 billion in 2020, according to a new report.

AbbVie's Humira turns in 18% surge in sales

AbbVie's Humira is the gift that just keeps on giving, and it presented the still-young drugmaker with a very big boost in the first quarter, powering its sales and earnings well beyond what had been projected.

AbbVie partners with Arabio for production in Saudi Arabia

As growth has slowed in some emerging markets, Western drugmakers are looking to second- and third-tier emerging markets to gain momentum. The Middle East has become the new hot spot for pharma, and AbbVie has found its way there.

Which brands grab the drug-spending title? AbbVie's Humira, AZ's Nexium lead the way

Which drugs cost U.S. health plans the most? Take a look at this year's iteration of Express Scripts' annual Drug Trend Report, and you'll find commentary on drug prices, the pharma industry, and American society. Not to mention a hint at which brands are best at getting themselves noticed.

The 10 best-selling drugs of 2013

It is the big sellers, the blockbusters--no, megablockbusters--that drug execs aspire to develop. And a look at the top 10 best-selling drugs globally can't help but impress with its big numbers.

More Humira sales gains help AbbVie meet forecasts

AbbVie's first full year as an independent pharma company is on the books, and the fast-growing drug that has buoyed it from the start continues to churn out sales growth. Once again, Humira revenues made double-digit gains, driving a fourth-quarter profit that matched analysts' expectations.